GeneDx Holdings (WGS) EBITDA (2020 - 2026)

GeneDx Holdings has disclosed EBITDA across 7 years of filings, most recently posting -$63.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 884.96% year-over-year to -$63.6 million; the TTM figure through Mar 2026 stood at -$78.0 million (down 105.55% YoY), while the FY2025 annual figure was -$20.9 million, up 59.69% from the prior year.
• EBITDA fell to -$63.6 million in Q1 2026, from -$17.7 million in the prior quarter.
• Over the last five years, EBITDA for WGS reached as high as $10.7 million in Q2 2025 and fell as low as -$308.8 million in Q4 2022.
• The 5-year median for EBITDA is -$29.0 million (2024), against an average of -$50.6 million.
• Annual changes were most pronounced in 2025 — EBITDA surged 136.95% — and 2026, when it tumbled 884.96%.
• A 5-year view of EBITDA shows it stood at -$308.8 million in 2022, then soared by 91.79% to -$25.3 million in 2023, then soared by 121.11% to $5.4 million in 2024, then plunged by 431.44% to -$17.7 million in 2025, then tumbled by 258.5% to -$63.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$63.6 million, -$17.7 million, and -$7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.